RecruitingPhase 2NCT06651593
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
Sponsor
M.D. Anderson Cancer Center
Enrollment
40 participants
Start Date
Jul 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Cemiplimab and a drug called SAR444881 for people with solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSAR444881
Given by IV
DRUGCemiplimab
Given by Iv
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06651593
Related Trials
Personalized Neoantigen Peptide Vaccines for Solid Tumors
NCT070022031 location
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
NCT072312111 location
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT045704235 locations
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT0393437223 locations
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873781 locations